NCT02238275已完成不适用
Post-Marketing Surveillance Study Micardis® Plus
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 8,135
- 主要终点
- Change from baseline in morning blood pressure
研究概览
简要总结
Study to evaluate efficacy and tolerability of Micardis® plus under usual daily-practice prescribing-conditions
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult (Age >= 18 years) males and females for whom a medical antihypertensive therapy is indicated
排除标准
- •Age < 18 years
研究组 & 干预措施
Patients with hypertension
干预措施: Micardis® plus (Drug)
结局指标
主要结局
Change from baseline in morning blood pressure
时间窗: Baseline, after 6 weeks
Change from baseline in classification of blood pressure
时间窗: Baseline, after 6 weeks
according to Word Health Organisation - Isolated systolic hypertension (WHO-ISH) - definition of 'Deutsche Hochdruckliga'
次要结局
- Number of patients with adverse drug reactions(up to 6 weeks)
- Assessment of efficacy by investigator on 5-point scale(after 6 weeks)
- Assessment of tolerability by investigator on a 5-point scale(after 6 weeks)
- Change from baseline in heart rate(Baseline, after 6 weeks)
研究者
相似试验
已完成
不适用
Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With HypertensionHypertensionNCT02242357Boehringer Ingelheim14,553
已完成
不适用
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential HypertensionHypertensionNCT02176850Boehringer Ingelheim19,870
已完成
不适用
Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)HypertensionNCT02262637Boehringer Ingelheim4,814
已完成
不适用
Micardis®. Observational Study in Patients With Essential HypertensionHypertensionNCT02200094Boehringer Ingelheim4,532
已完成
不适用
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With HypertensionHypertensionNCT02242838Boehringer Ingelheim6,336